Biomarkers can Reveal Timing for Cancer Drugs to Act
A biomarker named CD109 that can visualize blood vessel activity can optimize the timing of anticancer therapies including anti-angiogenics. Tumor growth needs the formation of new blood vessels (angiogenesis). Angiogenesis inhibitors alone have failed to invoke significant response rates or prolong survival in solid tumor patients.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer